BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 18070717)

  • 1. Role of autologous stem-cell transplantation in multiple myeloma.
    Attal M; Harousseau JL
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in therapy of multiple myeloma.
    Bladé J; Rosiñol L
    Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2007 Dec; 40(12):1101-14. PubMed ID: 17680020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous stem cell transplantation in the elderly including pre- and post-treatment options.
    Kumar SK; Hayman SR; Kyle RA
    Bone Marrow Transplant; 2007 Dec; 40(12):1115-21. PubMed ID: 17680019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of multiple myeloma: the changing landscape.
    Reece DE
    Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stem cell transplantation in multiple myeloma].
    Fukuda S; Sunami K; Sezaki T
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pretransplant therapy in patients with newly diagnosed myeloma undergoing autologous SCT.
    Kumar SK; Dingli D; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
    Bone Marrow Transplant; 2008 Jun; 41(12):1013-9. PubMed ID: 18332915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose treatment with autologous stem cell transplantation in multiple myeloma: past, present, and future.
    Björkstrand B; Gahrton G
    Semin Hematol; 2007 Oct; 44(4):227-33. PubMed ID: 17961721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies.
    Moreau P; Avet-Loiseau H; Harousseau JL; Attal M
    J Clin Oncol; 2011 May; 29(14):1898-906. PubMed ID: 21482979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of autologous hematopoietic stem cell transplantation in myeloma.
    Mehta J; Singhal S
    Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S28-S34. PubMed ID: 18724294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted treatments to improve stem cell outcome: old and new drugs.
    Raab MS; Breitkreutz I; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversy in multiple myeloma transplants: tandem autotransplants and mini-allografts.
    Vesole DH; Simic A; Lazarus HM
    Bone Marrow Transplant; 2001 Oct; 28(8):725-35. PubMed ID: 11781623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The evolving background for high-dose treatment for myeloma.
    Sirohi B; Powles R; Harousseau JL; Anderson KC
    Bone Marrow Transplant; 2007 Dec; 40(12):1097-100. PubMed ID: 17906702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hematopoietic stem cell transplantation in multiple myeloma].
    Vela-Ojeda J; Ruiz-Esparza MA
    Rev Invest Clin; 2005; 57(2):305-13. PubMed ID: 16524072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stem cell transplantation for multiple myeloma: current status and future directions.
    Caldera H; Giralt S
    Curr Hematol Rep; 2004 Jul; 3(4):249-56. PubMed ID: 15217554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.